 Menlo Therapeutics Inc. Nasdaq: MNLO Menlo or the Company, a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration FDA has approved ZILXITM minocycline topical foam, 1.5, for the treatment of inflammatory lesions of rosacea in adults. ZILXI, developed as FMX103 by Menlos wholly-owned subsidiary Foamix Pharmaceuticals Ltd. Foamix, is the first minocycline product of any kind to be approved by the FDA for use in rosacea. 